Processing

Please wait...

Settings

Settings

1. WO2000041696 - USE OF 5-HT5-LIGANDS IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISTURBANCES

Publication Number WO/2000/041696
Publication Date 20.07.2000
International Application No. PCT/EP2000/000143
International Filing Date 11.01.2000
Chapter 2 Demand Filed 28.07.2000
IPC
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
G01N 33/566 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
G01N 2500/02
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
G01N 2500/04
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
G01N 33/566
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagents ; where possible specific carrier or receptor proteins are classified with their target compounds
Applicants
  • BASF AKTIENGESELLSCHAFT [DE/DE]; D-67061 Ludwigshafen, DE (AllExceptUS)
  • GARCIA-LADONA, Francisco Javier [ES/DE]; DE (UsOnly)
  • SZABO, Laszlo [DE/DE]; DE (UsOnly)
  • STEINER, Gerd [DE/DE]; DE (UsOnly)
  • HOFMANN, Hans-Peter [DE/DE]; DE (UsOnly)
Inventors
  • GARCIA-LADONA, Francisco Javier; DE
  • SZABO, Laszlo; DE
  • STEINER, Gerd; DE
  • HOFMANN, Hans-Peter; DE
Agents
  • KINZEBACH, Werner ; Reitstötter, Kinzebach & Partner Postfach 86 06 49 81633 München, DE
Priority Data
199 00 673.311.01.1999DE
Publication Language German (DE)
Filing Language German (DE)
Designated States
Title
(DE) VERWENDUNG VON 5-HT5-LIGANDEN ZUR BEHANDLUNG NEURODEGENERATIVER UND NEUROPSYCHIATRISCHER STÖRUNGEN
(EN) USE OF 5-HT5-LIGANDS IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISTURBANCES
(FR) UTILISATION DE LIGANDS POUR LES RECEPTEURS 5-HT5 POUR LE TRAITEMENT DE TROUBLES NEURODEGENERATIFS ET NEUROPSYCHIATRIQUES
Abstract
(DE)
Die vorliegende Erfindung betrifft die Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neuropathologischer, insbesondere neurodegenerativer und/oder neuropsychiatrischer Störungen, die insbesondere bei cerebraler Ischämie, Schlaganfall, Epilepsie und Anfällen im allgemeinen, chronischer Schizophrenie, anderen psychotischen Erkrankungen, Demenz, insbesondere Alzheimer Demenz, demyelinisierende Erkrankungen, insbesondere Multipler Sklerose, und Gehirntumoren auftreten können. Die Erfindung betrifft auch Verfahren zur Identifizierung und Charakterisierung solcher Bindungspartner, insbesondere in Form von Screening-Verfahren.
(EN)
The invention relates to the use of binding partners for 5-HT5-receptors in the treatment of neuropathological and in particular neurodegenerative and/or neuropsychiatric disturbances which can occur notably in cases of cerebral ischaemia, cerebral stroke, epilepsy and attacks in general, chronic schizophrenia, other psychotic illnesses, dementia, notably Alzheimer's disease, demyelination diseases, notably multiple sclerosis, and brain tumors. The invention also relates to methods, especially screening methods, for identifying and characterizing such binding partners.
(FR)
L'invention concerne l'utilisation de partenaires de liaison pour les récepteurs 5-HT5 pour le traitement de troubles neuropathologiques, en particulier neurodégénératifs et/ou neuropsychiatriques qui peuvent apparaître en particulier dans le cas de l'ischémie cérébrale, de l'apoplexie cérébrale, de l'épilepsie et d'attaques en général, de la schizophrénie chronique, d'autres troubles psychotiques, de la démence, notamment de la maladie d'Alzheimer, de maladies démyélinisantes, notamment de la sclérose en plaques, et de tumeurs du cerveau. L'invention concerne également des procédés pour identifier et caractériser de tels partenaires de liaison, notamment des procédés de criblage.
Latest bibliographic data on file with the International Bureau